Aug 10, 2021
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...
144
Dec 13, 2019
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...
64
Dec 13, 2018
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
NCT03752541: Efficacy and Safety Evaluation of BCMA-UCART AllogeneicT-cells with Anti-BCMA CAR Chimeric Antigen Receptor）in the Treatment...
57
Dec 12, 2018
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With Gamma Secretase Inhibitor (JSMD194)
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent...
104
Dec 10, 2017
NCT03218683: Phase 1/2: Study of AZD5991 Alone or with Venetoclax in Relapsed Hem Malignancies
NCT03218683: Phase 1/2: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies....
89
Dec 23, 2016
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
Bellini RRMM A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as...
191
Dec 1, 2016
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma Establish the MTD of Lintuzumab-Ac225 as monotherapy...
65
Dec 7, 2007
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After ASCT -TT2
NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2...
123